Patents Assigned to Bioleaders Corporation
-
Publication number: 20120164174Abstract: The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.Type: ApplicationFiled: June 25, 2010Publication date: June 28, 2012Applicants: BIOLEADERS CORPORATION, KOOKMIN UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION, THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Moon-Hee Sung, Haryoung Poo, Chul Joong Kim, Young-Ki Choi, Yong Taík Lim, Dong Jin Jeong, Sang-Mu Shim
-
Publication number: 20120156172Abstract: The present invention relates to a new microorganism Weissella cibaria BLS13, and more specifically, to a Kimchi-derived new microorganism Weissella cibaria BLS13 which activates an inhibitory effect on avian influenza viruses, and to uses thereof. According to the present invention, the Weissella cibaria BLS13 or a culture medium thereof contains a substance having an anti-viral function, and thus can be used advantageously in feed additives, fermentation products, foods and medicine.Type: ApplicationFiled: June 17, 2010Publication date: June 21, 2012Applicants: BIOLEADERS CORPORATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, KOOKMIN UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATIONInventors: Jong-Bok Rho, Haryoung Poo, Young-Ki Choi, Chul Joong Kim, Moon-Hee Sung
-
Publication number: 20120010130Abstract: The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (?-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient. The composition containing poly-gamma-glutamic acid as an effective ingredient according to the present invention, is effective for use as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, BIOLEADERS CORPORATIONInventors: Moon-Hee SUNG, Chul Joong KIM, Haryoung POO, Young-Ki CHOI, Il Han LEE, Dai-Won YOO
-
Patent number: 8080402Abstract: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Anal3 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Anal3 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability.Type: GrantFiled: January 11, 2007Date of Patent: December 20, 2011Assignees: Bioleaders Corporation, Korea Research Institute of Bioscience and Biotechnology, Chosun UniversityInventors: Moon-Hee Sung, Seung-Pyo Hong, Jong-Su Lee, Chang-Min Jung, Kyung-Soo Hahm, Dong-Gun Lee, Yoon Kyung Park, Chul-Joong Kim, Ha-Ryoung Poo
-
Patent number: 7871816Abstract: Expression vectors that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-?-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus. Methods for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.Type: GrantFiled: November 13, 2007Date of Patent: January 18, 2011Assignees: Bioleaders Corporation, Korea Research Institute of Bioscience and BiotechnologyInventors: Moon-Hee Sung, Ha Ryoung Poo, Jong Soo Lee, Chang Min Jung, Seung Pyo Hong, Chul-Joong Kim, Sue-nie Park, Hyun-mi Pyo
-
Publication number: 20100255040Abstract: The present invention relates to a composition for improving cellular immunity, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a composition for improving cellular immunity comprising poly-gamma-glutamic acid, which has effects of inducing enhancement of TLR-mediated Th1 cellular immunity and improving antigen presenting activity to maintain the improved activity. The inventive composition comprising an effective dose of poly-gamma-glutamic acid has very little toxicity and side effects, and can be added to a vaccine composition for preventing and treating animal viral or bacterial infections and cancer, or a vaccine composition for preventing and treating human viral or bacterial infections and cancer to show cellular immunity-enhancing effects.Type: ApplicationFiled: October 15, 2007Publication date: October 7, 2010Applicant: BIOLEADERS CORPORATIONInventors: Moon-Hee Sung, Chul Joong Kim, Haryoung Poo, Il Han Lee, Yang-Hyun Kim
-
Publication number: 20100256050Abstract: The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (?-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient. The composition containing poly-gamma-glutamic acid as an effective ingredient according to the present invention, is effective for use as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.Type: ApplicationFiled: September 13, 2007Publication date: October 7, 2010Applicant: BIOLEADERS CORPORATIONInventors: Moon-Hee Sung, Chul Joong Kim, Haryoung Poo, Young-Ki Choi, Il Han Lee, Dai-Won Yoo
-
Publication number: 20100226891Abstract: The present invention relates to a fusion protein in which a myostatin mature protein is fused to a multimer of myostatin-derived antigenic peptide Myo-2, a surface expression vector containing a polynucleotide encoding the fusion protein, a recombinant microorganism transformed with the vector, and a feedstuff additive or a pharmaceutical composition containing the microorganism as an effective ingredient. The feedstuff additive or pharmaceutical composition according to the present invention can be used for muscle development and regulation of muscle growth in livestock and poultry, as well as for preventing and treating muscle-wasting diseases and degenerative diseases such as muscular dystrophy, muscular atrophy and the like. In addition, the transformed strain shows the same effect even if the strain itself after culture thereof is directly used, and thus it is very economical.Type: ApplicationFiled: November 30, 2007Publication date: September 9, 2010Applicant: BIOLEADERS CORPORATIONInventors: Moon-Hee Sung, Chul Joong Kim, Haryoung Poo, Ji Yeon Kim, Young Suk Kim, Long Chun Xu
-
Publication number: 20100196956Abstract: Disclosed herein are an aldolase gene promoter and the use thereof, more particularly, disclosed are a promoter of aldolase gene derived from Lactobacillus casei, having a base sequence of SEQ ID NO: 1, an expression vector containing said promoter, and a recombinant microorganism transformed with said expression vector. The recombinant microorganism transformed with the expression vector containing the disclosed promoter can effectively express a target protein on the surface thereof, and thus will be useful as vaccine vehicles and the like.Type: ApplicationFiled: March 21, 2008Publication date: August 5, 2010Applicants: Bioleaders Corporation, Korea Research Institute of Bioscience and BiotechnologyInventors: Moon Hee Sung, Chul Joong Kim, Seung-Pyo Hong, Haryoung Poo, Il Han Lee, Ji Yeon Kim, Kwang Kim
-
Publication number: 20100036093Abstract: Provided is a poly-?-glutamic acid derivative having appropriately controlled hydrophilicity, which can be processed into a form of fine particles. Provided is a PGA derivative in a form of fine particles having a particle diameter of 50 to 1,000 nm, which is obtained by introducing cholesterol into poly-?-glutamic acid (PGA). Thus, the PGA particles can be mixed with various biological materials (e.g., medicament) so as to be used in various applications in the field of biotechnology. Specifically, it can be used as a carrier of a medicament, or the like. Further, it is also made possible to use PGA in various applications in the field of nanotechnology that is studied in recent years.Type: ApplicationFiled: May 9, 2007Publication date: February 11, 2010Applicants: OSAKA UNIVERSITY, GENOLAC BL CORPORATION, BIOLEADERS CORPORATIONInventors: Hiroshi Uyama, Yasushi Osanai, Moon-hee Sung
-
Patent number: 7582466Abstract: Bacillus subtilis var. chungkookjang, accession no. KCTC 0697BP, a salt-resistant B. subtilis variant isolated from “chungkookjang,” a traditional Korean fermented soy bean paste. This B. subtilis variant produces poly-gamma-glutamic acid (or poly-gamma-glutamate, ?-PGA), an edible, soluble, anionic, and biodegradable high molecular-weight polymer. Bacillus subtilis var. chungkookjang produces ?-PGA with a higher molecular weight than other extracellular ?-PGAs derived from general Bacillus sp. strains. Accordingly, the ?-PGA produced by Bacillus subtilis var. chungkookjang can be utilized for the development of high value-added products, such as cosmetics, absorption agents, and biodegradable plastic materials.Type: GrantFiled: December 31, 2005Date of Patent: September 1, 2009Assignee: Bioleaders CorporationInventors: MoonHee Sung, DaeHeoun Baek, SeungGoo Lee, JaeJun Song, SeungPyo Hong, YoonHo Choi, SunYoung Shin, JaeSuk Han, Makoto Ashiuchi, Kenji Soda
-
Publication number: 20090186804Abstract: The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation.Type: ApplicationFiled: December 22, 2006Publication date: July 23, 2009Applicant: BIOLEADERS CORPORATIONInventors: Moon-Hee Sung, Chung Park, Seung-Pyo Hong, Haryoung Poo, Tae-Woo Kim
-
Patent number: 7553636Abstract: The present invention relates to a surface expression vector having pgsBCA, a gene coding poly-gamma-glutamate synthetase and a method for expression of target protein at the surface of microorganism using the vector. The vector, in which foreign genes are inserted, transforms microorganisms and makes foreign proteins expressed stably on the surface of microorganisms.Type: GrantFiled: August 9, 2002Date of Patent: June 30, 2009Assignees: Bioleaders Corporation, M.D. Lab Co., Ltd., Department of Veterinary Science Chung Nam UniversityInventors: Moon-Hee Sung, Seung-Pyo Hong, Jong-Su Lee, Chang-Min Jung, Chul-Joong Kim, Kenji Soda, Makoto Ashiuchi
-
Patent number: 7501262Abstract: To provide a promoter, a recombinant DNA, a gene expression vector, an expression vector, and a transformant, which are capable of expressing a gene without inducing gene expression with an inducer; and a method for producing a protein and a kit therefor, which can be operated easily and performed inexpensively by convenient and inexpensive steps.Type: GrantFiled: November 15, 2006Date of Patent: March 10, 2009Assignees: Bioleaders Corporation, Takara Bio Inc.Inventors: Moon-Hee Sung, Seung-Goo Lee, Seung-Pyo Hong, Hwa-Jung Seo
-
Publication number: 20080247986Abstract: The present invention relates to a hyaluronidase inhibitor containing poly-gamma-glutamic acid (PGA) as an active ingredient, a composition for maintaining skin elasticity and a composition for improving allergy, wherein each of the compositions contains PGA as an active ingredient. The inventive compositions containing PGA are effective in maintaining skin moisturization and skin elasticity by effectively inhibiting the activity of hyaluronidase which is an enzyme that degrades hyaluronic acid present in the skin dermis. Also, the compositions can relieve allergic symptoms by inhibiting the permeability of inflammatory cells.Type: ApplicationFiled: October 31, 2005Publication date: October 9, 2008Applicant: BIOLEADERS CORPORATIONInventors: Moon Hee Sung, Chung Park, Jae Chul Choi, Hiroshi Uyama, So Lim Park
-
Patent number: 7425438Abstract: Expression vectors are described that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-?-glutamic acid synthetase complex (pgsBCA) of a Bacillus sp. strain, and genes that encode virion capsid proteins, tumor-associated proteins of human papillomavirus, Methodology for preparing the foregoing vectors, vaccines and transformed microorganisms are also described.Type: GrantFiled: October 17, 2003Date of Patent: September 16, 2008Assignees: Bioleaders Corporation, Korea Research Institute of Bioscience and BiotechnologyInventors: Moon-Hee Sung, Ha Ryoung Poo, Jong-Soo Lee, Chang-Min Jung, Seong-Pyo Hong, Chul-Joong Kim, Sue-nie Park, Hyun-mi Pyo
-
Publication number: 20080152615Abstract: The present invention relates to a composition for an immunopotentiator (adjuvant) containing poly-gamma-glutamic acid and a composition for a vaccine containing the immunopotentiator, and more particularly, to an immunopotentiator containing poly-gamma-glutamic acid capable of enhancing antibody production rate by administering it to an animal together with antigen having low immunogenicity, and a composition for a vaccine containing the immunopotentiator and antigen. The inventive adjuvant has almost no toxicity and side effects, and show high antibody titer even when it is used with antigen having poor immunogenicity, so it can be used by adding to medical composition including preventive or curative vaccine for non-contagious chronic diseases as well as cancer, especially prostatic carcinoma, colon carcinoma, lung cancer, breast cancer, ovarian cancer, head and neck cancer, pudendum cancer, bladder cancer, brain tumor and glioma.Type: ApplicationFiled: December 6, 2005Publication date: June 26, 2008Applicants: BIOLEADERS CORPORATION, M.D. LAB CO., LTD, Korea Research Institute Of Bioscience and BiotechnologyInventors: Moon-Hee Sung, Chul-Joong Kim, Ha Ryoung Poo, Seung Pyo Hong, Jong Soo Lee, Ji Youn Kim
-
Patent number: 7255855Abstract: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Ana13 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from Bacillus sp. strains and involved in the synthesis of poly-gamma-glutamate. Moreover, the present invention relates to lactic acid-forming bacteria having each of the peptide antibiotics P5 15 and Ana13 43 expressed on their surface, and the use thereof. According to the present invention, the peptide antibiotics can be expressed on the surface of various microorganisms transformed with the surface expression vectors. The inventive method for the surface expression of the peptide antibiotics allows the peptide antibiotics to be mass-produced without a purification process. Thus, the inventive method has very high industrial applicability.Type: GrantFiled: February 27, 2004Date of Patent: August 14, 2007Assignee: Bioleaders CorporationInventors: Moon-Hee Sung, Seung-Pyo Hong, Jong-Su Lee, Chang-Min Jung, Kyung-Soo Hahm, Dong-Gun Lee, Yoon Kyung Park, Chul-Joong Kim, Ha-Ryoung Poo
-
Patent number: 7183077Abstract: To provide a promoter, a recombinant DNA, a gene expression vector, an expression vector, and a transformant, which are capable of expressing a gene without inducing gene expression with an inducer; and a method for producing a protein and a kit therefor, which can be operated easily and performed inexpensively by convenient and inexpensive steps.Type: GrantFiled: April 26, 2001Date of Patent: February 27, 2007Assignees: BioLeaders Corporation, Takara Bio Inc.Inventors: Moon-Hee Sung, Seung-Goo Lee, Seung-Pyo Hong, Hwa-Jung Seo
-
Patent number: 7091010Abstract: Salt-resistant Bacillus subtilis var. chungkookjang, accession no. KCTC 0697BP, separated from “chungkookjang” a traditional Korean fermented soy bean paste and its poly-gamma-glutamic acid (or poly-gamma-glutamate, g-PGA), an edible, soluble, anionic, and biodegradable high molecular-weight polymer. Bacillus subtilis var. chungkookjang produces g-PGA with a higher molecular weight than other extracellular g-PGAs derived from general Bacillus sp. strains and can be utilized for the development of high value-added products, such as cosmetics, absorption agents, and biodegradable plastic materials.Type: GrantFiled: August 11, 2001Date of Patent: August 15, 2006Assignee: Bioleaders CorporationInventors: MoonHee Sung, DaeHeoun Baek, SeungGoo Lee, JaeJun Song, SeungPyo Hong, YoonHo Choi, SunYoung Shin, JaeSuk Han, Makoto Ashiuchi, Kenji Soda